
Resident @BrighamMedRes | MD @WeillCornell | AB @Harvard | Interests: gastroenterology, advanced endoscopy, EndoHepatology
Joined May 2024
- Tweets17
- Following122
- Followers37
- Likes224
Pinned Tweet
Incredibly grateful to have matched at @BrighamMedRes for Internal Medicine residency! Excited to be heading back to Boston for this next step in my training.
Everything owed to my family and mentors at @WeillCornell + @MSKCancerCenter for their unconditional support. #Match2025
Patrick Magahis, MD retweeted
Out now in @EndoscopyJrnl: a cost-effectiveness analysis of EUS-CDS with LAMS vs ERCP-BD with SEMS for primary palliation of malignant distal biliary obstruction.
Markov model, US payer perspective, 1yr horizon.
ICER $47,711/QALY. Cost-effective when CBD >15 mm.
@PatrickMagahis
EUS-CDS vs. ERCP-BD for primary palliation of malignant distal biliary obstruction: a cost–effectiveness modeling analysis
Find the article at: doi.org/10.1055/a-2837-1405
Patrick T. Magahis et al.
#Endoscopy #Gastroenterology @ESGE_news
@PatrickMagahis @ReemSharaiha
Happy to share our newest paper comparing #EUS vs #ERCP for #MDBO:
💰EUS cost-effective over ERCP (ICER $47k)
✅ Driven by ⬇️ initial cost (despite LAMS), ⬇️ reintervention rates, ⬇️ pancreatitis, ⬆️ technical success.
📊 Robust on sensitivity analyses, hospital-level analysis
EUS-CDS vs. ERCP-BD for primary palliation of malignant distal biliary obstruction: a cost–effectiveness modeling analysis
Find the article at: doi.org/10.1055/a-2837-1405
Patrick T. Magahis et al.
#Endoscopy #Gastroenterology @ESGE_news
@PatrickMagahis @ReemSharaiha
🤔 Anatomy, expertise, patient risk factors should still drive drainage modality
💭 RCTs comparing EUS vs ERCP in all comers with MDBO critically needed
🏋️ Expanding therapeutic EUS training/accessibility is essential
Thank you to my mentors @ReemSharaiha and #SriHariMahadev!
1
49
Patrick Magahis, MD retweeted
Thank you @ASGEendoscopy and @DDWMeeting for allowing us to present our work on developing and validating an EUS liver model for training in endohepatology!
#DDW2026
Patrick Magahis, MD retweeted
Magahis et al compare "Outcomes of endoscopic ultrasound–guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique." giejournal.org/article/S0016…
#GITwitter
@PatrickMagahis @ReemSharaiha @MarkHanscomMD
Patrick Magahis, MD retweeted
Drs Patrick T. Magahis and SriHari Mahadev discuss “Outcomes of endoscopic ultrasound–guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique." youtu.be/cFEn4tbjCuI
#GITwitter
@PatrickMagahis @ReemSharaiha @MarkHanscomMD
Patrick Magahis, MD retweeted
Online now in GIE’s Articles in Press: "Outcomes of EUS-guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique" by Patrick T. Magahis et al. giejournal.org/article/S0016…
#GITwitter
@PatrickMagahis @MarkHanscomMD @ReemSharaiha
Happy to share our recent @JNCCN study on #Cdiff infection in patients on #immunotherapy p/w diarrhea:
👉Common (18%)
👉⬆️G3-4 diarrhea but antibiotic tx alone sufficient for most
👉24% required steroids for concomitant immune-related enterocolitis (1/2)
doi.org/10.6004/jnccn.2024.7…
🔑 Prompt CDI testing for all ➡️ if +, abx + close f/up ➡️ if persistent sx, endoscopy + consider steroids for concomitant irEC
Thank you to my mentor and study PI @DavidFaleckMD + all our @MSKCancerCenter co-authors @MLaszkowskaMD @DeepikaSatishMD @mini_kamboj @EBabady! (2/2)
2
271
Patrick Magahis, MD retweeted
Replying to @MondayNightIBD @DCharabaty
55M w/ UC x30y. Prior 5-ASA, 6MP. On IFX 5 mg/kg q8w x5y. Mild UC sx before infusions.
🔦Last scope 1y ago: Mayo 0.
Now FCP 141, IFX level 3.
New dx: metastatic melanoma → onc is starting nivolumab.
What do you recommend for his UC?
17%Stop IFX, monitor on Nivo
37%⬆️IFX 5mg/kg q4wks+Nivo
5%Stop IFX, start Upa+Nivo
41%Stop IFX, start VDZ+Nivo
87 votes • Final results Patrick Magahis, MD retweeted
So excited for this all-star intern crew to join us in June!! Huge congratulations on a fantastic and well-deserved #match2025! 🎉
Patrick Magahis, MD retweeted
Featured today by @MSKLibrary: Differences in Ancestry and Presence of Gastric Precursor Lesions in Individuals With Young- and Average-Onset Gastric Cancer
#PrecursorLesions #GastricCancer #StomachCancer #EarlyOnsetCancer #CancerGenetics #CancerPrevention #CancerResearch
@PatrickMagahis @kanikaarora316 @SantoshVardhana @LumishMelissa @AndreaCercek
@YJanjigianMD @MFBerger1 @VStrongMD @StadlerZsofia @MLaszkowskaMD
dx.doi.org/10.1002/cam4.7045…
Patrick Magahis, MD retweeted
Congratulations to @PatrickMagahis @AnkitChhoda and the rest of the team for their recent publication in ACG on the risk of pancreatitis after EUS-FNA!
🔑 The pooled risk of pancreatitis was 1.4% after EUS-FNA, most cases of which (67%) were mild.
journals.lww.com/ajg/fulltex…
Patrick Magahis, MD retweeted
Here’s a closer look at recent #JITC article “Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors” by @PatrickMagahis & @DavidFaleckMD from @WeillCornell & @MSKCancerCenter. 1/11
Patrick Magahis, MD retweeted
Happy to share our experience using open capsule budesonide for successful treatment of immune-related enteritis. Grateful for my fantastic team @MSKCancerCenter who help treat these pts and made this study possible and ⭐️ med student @PatrickMagahis for putting this together.
New #JITC article: Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors bit.ly/4daLo9Z @PatrickMagahis @DavidFaleckMD
Patrick Magahis, MD retweeted
New #JITC article: Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors bit.ly/4daLo9Z @PatrickMagahis @DavidFaleckMD
























